瑞戈非尼
医学
替莫唑胺
临床终点
肿瘤科
内科学
危险系数
随机对照试验
贝叶斯概率
临床研究阶段
贝伐单抗
中期分析
贝叶斯定理
相伴的
增加物
临床试验
外科
洛莫司汀
性能状态
核医学
前瞻性队列研究
放射科
多元分析
无进展生存期
置信区间
放射治疗
可解释性
胶质母细胞瘤
生存分析
相对风险
耐火材料(行星科学)
医学物理学
作者
Patrick Yung Wen,Donald A. Berry,Meredith Buxton,Howard Colman,John de Groot,Michael K. Lim,Ingo K. Mellinghoff,James R. Perry,Michael Weller,Nicolas Blondin,Omar Hameed Butt,Denise M. Damek,Macarena Ines de la Fuente,Jan Drappatz,Erin Dunbar,Pierre Giglio,Emma Maria Viktoria Hyddmark,Fabio M. Iwamoto,Kurt A. Jaeckle,Lyndon Kim
摘要
PURPOSE: GBM AGILE (ClinicalTrials.gov identifier: NCT03970447) is a phase II/III Bayesian adaptive platform registration trial testing multiple arms against a common control; the primary end point is overall survival (OS). Regorafenib, a multikinase inhibitor, showed OS benefit in recurrent (RD) glioblastoma in the phase II REGOMA trial and entered GBM AGILE as the first investigational arm. METHODS: Patient subtypes included in the regorafenib arm of GBM AGILE were newly diagnosed unmethylated (NDU) and RD glioblastoma. Prospective defined sets of subtypes, or arm signatures, were NDU, RD, and all (NDU + RD). As the first investigational arm in GBM AGILE, regorafenib was equally randomized to the control arm. Treatment in the control arm is temozolomide + radiotherapy (in newly diagnosed) or lomustine (in RD). Efficacy was assessed by OS hazard ratio (HR), arm/control, and demonstrated when the Bayesian probability of benefit (HR <1.00) was ≥98%. Analysis was performed monthly for limited efficacy, which occurs when the Bayesian predictive power is <25% for all signatures, and determines stopping enrollment. Follow-up continued for 12 months after accrual stopped. RESULTS: When the predictive power was <25% in all predefined signatures for regorafenib, accrual stopped for limited efficacy. The final analysis did not demonstrate OS improvement in the regorafenib arm in RD nor NDU glioblastoma. Median HRs were 1.05 (NDU), 1.07 (RD), and 1.07 (all) with final probabilities of benefit (HR <1.00) of 0.421 (NDU), 0.312 (RD), and 0.296 (all). Regorafenib was associated with increased toxicity relative to control. CONCLUSION: GBM AGILE did not show superiority of regorafenib over control in RD (lomustine) or NDU (temozolomide + radiotherapy) glioblastoma, yet caused increased toxicities. Regorafenib has been removed from National Comprehensive Cancer Network guidelines as a treatment option for RD.
科研通智能强力驱动
Strongly Powered by AbleSci AI